Oregon's Cascade Chemistry looks to boost its American-made API production with $14M investment
Amid heightened calls for American-made drugs, a suite of contract manufacturers are making big investments to boost supply. Now, an Oregon CDMO is stepping up to the plate to grow its API contract business.
Cascade Chemisty will triple its total floor space with a $14 million investment, the company said in a press release. Site construction is already underway on a 28,000 square-foot building, which will include suites for Phase I and Phase II manufacturing with flow hydrogenation and reactors up to 400 liters.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.